Logo wahanariau.com
  2. New jersey

New jersey

Index
Globenewswire

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

Selasa, 27 Januari 2026 - 22:09:08 Wib
Globenewswire

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Kamis, 15 Januari 2026 - 20:12:04 Wib
Globenewswire

Impulse Dynamics® Announces New Chief Financial Officer

Rabu, 14 Januari 2026 - 05:20:48 Wib
Globenewswire

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Selasa, 13 Januari 2026 - 05:45:26 Wib
Globenewswire

Synchronoss Memamerkan Perluasan Platform Personal Cloud, Momentum Capsyl, dan Menampilkan Pratinjau Penawaran Baru di CES 2026

Rabu, 07 Januari 2026 - 19:01:22 Wib
Globenewswire

Synchronoss Showcases Expanded Personal Cloud Platform, Capsyl Momentum, and Previews New Offering at CES 2026

Rabu, 07 Januari 2026 - 05:53:45 Wib
Globenewswire

Verisk Ends Effort to Acquire AccuLynx

Senin, 29 Desember 2025 - 23:41:21 Wib
Globenewswire

DALI Alliance Meluncurkan Spesifikasi Pengujian dan Sertifikasi untuk Gateway Nirkabel ke DALI

Selasa, 23 Desember 2025 - 21:29:23 Wib
Globenewswire

DALI Alliance Launches Test and Certification Specifications for Wireless to DALI Gateways

Senin, 22 Desember 2025 - 21:22:22 Wib
Globenewswire

Impulse Dynamics Completes $158M Financing Round

Kamis, 11 Desember 2025 - 01:16:43 Wib
Globenewswire

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Kamis, 11 Desember 2025 - 00:07:40 Wib
Globenewswire

AUSTEDO® (deutetrabenazine) Tablets and AUSTEDO XR® (deutetrabenazine) Extended-release Tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Selasa, 11 November 2025 - 02:36:18 Wib
Globenewswire

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis

Senin, 03 November 2025 - 21:44:06 Wib
Globenewswire

Impulse Dynamics® Celebrates CMS National Coverage Determination for CCM® Therapy

Kamis, 30 Oktober 2025 - 04:34:19 Wib
Globenewswire

MISTRAS Group Partnering with Villari to Offer Wireless Crack-Detection Sensors for Critical Steel Assets

Selasa, 14 Oktober 2025 - 20:48:36 Wib
Globenewswire

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Sabtu, 11 Oktober 2025 - 02:25:54 Wib
Globenewswire

Verisk Names Saurabh Khemka President of Underwriting Solutions

Selasa, 30 September 2025 - 20:00:00 Wib
Globenewswire

Patients Taking AUSTEDO XR® (deutetrabenazine) Extended-release Tablets Reported Symptom Improvement and High Satisfaction

Senin, 22 September 2025 - 02:25:11 Wib
Globenewswire

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Senin, 22 September 2025 - 02:24:05 Wib
Globenewswire

AvePoint Announces Dual Listing on the Singapore Exchange to Continue Global Expansion

Sabtu, 20 September 2025 - 01:09:47 Wib
Globenewswire

AvePoint Announces Pricing of Public Offering

Selasa, 16 September 2025 - 20:00:00 Wib
Globenewswire

Kyowa Kirin Announces Late-Breaking Abstract Presentation at the European Academy of Dermatology and Venerology Congress

Kamis, 11 September 2025 - 19:30:00 Wib
Berita

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Rabu, 10 September 2025 - 04:08:15 Wib
Globenewswire

$152 Billion and Rising: New Report Shows Insurance Industry Facing Growing Average Annual Losses from Natural Catastrophes

Selasa, 02 September 2025 - 23:07:59 Wib
Globenewswire

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

Kamis, 28 Agustus 2025 - 22:10:36 Wib